Lilly MALO :

​

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in
Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease who are at Increased
Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes)

​

Intervention-Specific Appendix (ISA2) for Retatrutide in Participants with Metabolic
Dysfunction-Associated Steatotic Liver Disease

​

Intervention-Specific Appendix (ISA1) for Tirzepatide in Participants with Metabolic
Dysfunction-Associated Steatotic Liver Disease

​

Study Details | NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | ClinicalTrials.gov